Synta Releases Preclinical, Clinical Data On STA-9090
Synta is currently enrolling patients in a Phase 2 single-arm, open-label, single-agent study of STA-9090 in patients with stage IIIB or IV non-small cell lung cancer, with patient
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.
The article, entitled ‘Hereditary Breast and Ovarian Cancer Testing Integration and Outcomes within Community Oncology Practices,’ was published in the February 2010 issue of the journal Community Oncology.